427 research outputs found
The role of variation in genetic susceptibility to soybean rust on the photosynthetic competence of infected leaves.
Three soybean rust infection types have been reported: 1) tan lesions indicate a compatible and susceptible reaction, 2) red- brown (RB) lesion type has been associated with few non-sporulating uredinia representing a resistant reaction, and 3) immune reaction with no visible evidence of infection. Differences among cultivars would imply genotypic differences in tolerance, which can be define as the ability of the host to endure the presence of the pathogen with reduced disease symptoms and/or damages. Soybean rust-induced yield loss has been associated with reduction in light interception due to premature leaf loss and the lesions on the remaining green leaves. Incorporation of the effect of the pathogen on photosynthetic efficiency of disease leaves from different soybean cultivars in model to predict production might increase the accuracy and precision of the estimates supply by this model. Bastiaans (1991) proposed the concept of a "virtual lesion" and developed a simple model Y= (1-x)? to fit empirical data and describe the relationship between the reduction in relative photosynthesis in a diseased leaf (Y), and the disease severity (x). The value of â indicates whether the effect of disease on photosynthesis is higher (? > 1), lower (? < l) or equal (? = 1) to that accounted for by the observed diseased area. Reliable estimate of disease effects on growth and yield depends on the ability to accurate quantify the parameter ?. The objective of the current study was to determine the role of host-plant variation in disease susceptibility on soybean leaf gas exchange in field and control environment studies. The specific objectives are to quantify the ? value for SBR-infected leaves as influenced by plant growing conditions and genetic variation in disease susceptibility.Edição do Proceedings of the National Soybean Rust Symposium, New Orleans, 2009
A low pH enzyme linked immunoassay using two monoclonal antibodies for the serological detection and monitoring of breast cancer.
A new, simple and sensitive low pH ELISA method has been developed to measure serum levels of tumour associated antigens detectable by monoclonal antibodies HMFG1 and HMFG2. We examined sera from healthy controls, patients with neoplastic and non-neoplastic conditions of breast, liver and gastrointestinal tract. The majority of patients with metastatic breast cancer had elevated serum antigens (69% HMFG1, 72% HMFG2) compared to healthy controls (6.3% HMFG1, 3.0% HMFG2) or patients with benign breast disease (17% HMFG1, 4% HMFG2). There was no discrimination using these assays between patients with neoplastic and non-neoplastic conditions of liver and gastrointestinal tract. This new method promises to be of value in the assessment and management of patients with breast cancer
Quantum key distribution with 1.25 Gbps clock synchronization
We have demonstrated the exchange of sifted quantum cryptographic key over a
730 meter free-space link at rates of up to 1.0 Mbps, two orders of magnitude
faster than previously reported results. A classical channel at 1550 nm
operates in parallel with a quantum channel at 845 nm. Clock recovery
techniques on the classical channel at 1.25 Gbps enable quantum transmission at
up to the clock rate. System performance is currently limited by the timing
resolution of our silicon avalanche photodiode detectors. With improved
detector resolution, our technique will yield another order of magnitude
increase in performance, with existing technology.Comment: 6 pages, 3 figures, 99 kB .pdf documen
Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease
Background: Gestational trophoblastic disease (GTD) is a rare complication of pregnancy, ranging from molar pregnancy to choriocarcinoma. Patients with persistent disease require treatment with chemotherapy. For the vast majority, prognosis is excellent. Occasionally, GTD is complicated by hyperthyroidism, which may require treatment. This is thought to occur due to molecular mimicry between human chorionic gonadotrophin (HCG) and thyroid-stimulating hormone (TSH), and hence cross-reactivity with the TSH receptor. Hyperthyroidism usually resolves as the GTD is successfully treated and correspondingly HCG levels normalise.
Methods: This paper reviews cases of GTD treated over a 5-year period at one of the three UK centres and identifies the prevalence of hyperthyroidism in this population. Four cases with clinical hyperthyroidism are discussed.
Results: On review of the 196 patients with gestational trophoblastic neoplasia treated with chemotherapy in Sheffield since 2005, 14 (7%) had biochemical hyperthyroidism. Of these, four had evidence of clinical hyperthyroidism.
Conclusion: Concomitant biochemical thyroid disease in patients with GTD is relatively common, and measurement of thyroid function in patients with persistent GTD is, therefore, important. The development of hyperthyroidism is largely influenced by the level of HCG and disease burden, and usually settles with treatment of the persistent GTD. However, rarely the thyroid stimulation can have potentially life-threatening consequences
Changes in vitamin and mineral supplement use after breast cancer diagnosis in the Pathways Study: a prospective cohort study
BACKGROUND: Vitamin and mineral supplement use after a breast cancer diagnosis is common and controversial. Dosages used and the timing of initiation and/or discontinuation of supplements have not been clearly described. METHODS: We prospectively examined changes in use of 17 vitamin/mineral supplements in the first six months following breast cancer diagnosis among 2,596 members (28% non-white) of Kaiser Permanente Northern California. We used multivariable logistic regression to examine demographic, clinical, and lifestyle predictors of initiation and discontinuation. RESULTS: Most women used vitamin/mineral supplements before (84%) and after (82%) diagnosis, with average doses far in excess of Institute of Medicine reference intakes. Over half (60.2%) reported initiating a vitamin/mineral following diagnosis, 46.3% discontinuing a vitamin/mineral, 65.6% using a vitamin/mineral continuously, and only 7.2% not using any vitamin/mineral supplement before or after diagnosis. The most commonly initiated supplements were calcium (38.2%), vitamin D (32.01%), vitamin B6 (12.3%) and magnesium (11.31%); the most commonly discontinued supplements were multivitamins (17.14%), vitamin C (15.97%) and vitamin E (45.62%). Higher education, higher intake of fruits/vegetables, and receipt of chemotherapy were associated with initiation (p-values <0.05). Younger age and breast-conserving surgery were associated with discontinuation (p-values <0.05). CONCLUSIONS: In this large cohort of ethnically diverse breast cancer patients, high numbers of women used vitamin/mineral supplements in the 6Â months following breast cancer diagnosis, often at high doses and in combination with other supplements. The immediate period after diagnosis is a critical time for clinicians to counsel women on supplement use
Quantum key distribution and 1 Gbit/s data encryption over a single fibre
We perform quantum key distribution (QKD) in the presence of 4 classical
channels in a C-band dense wavelength division multiplexing (DWDM)
configuration using a commercial QKD system. The classical channels are used
for key distillation and 1 Gbps encrypted communication, rendering the entire
system independent from any other communication channel than a single dedicated
fibre. We successfully distil secret keys over fibre spans of up to 50 km. The
separation between quantum channel and nearest classical channel is only 200
GHz, while the classical channels are all separated by 100 GHz. In addition to
that we discuss possible improvements and alternative configurations, for
instance whether it is advantageous to choose the quantum channel at 1310 nm or
to opt for a pure C-band configuration.Comment: 9 pages, 7 figure
Waiting times for systemic cancer therapy in the United Kingdom in 2006
This audit was conducted to measure waiting times for systemic cancer therapy across the United Kingdom. All patients, aged 16 years or older, commencing their first course of systemic therapy between 13 November and 19 November 2006 were eligible for inclusion. Data on 936 patients from 81 hospital sources were collected. Systemic therapy is largely given in compliance with national waiting time targets. In terms of the Joint Council for Clinical Oncology (JCCO) targets, 84% of patients commence treatment within 21 days and 98% of patients complied with the Department of Health target that treatment should follow within 31 days of the decision being agreed with the patient. Only 76% complied with the Department of Health 62-day target from GP referral to first definitive treatment. However, the date of urgent referral by the GP was not submitted for most patients in our survey, leaving a sample of only 84 out of 936 patients (9% of total) suitable for this analysis. There was only a 3- to 5-day difference between the waiting times for systemic therapy for patients categorised as urgent compared with routine. Locally agreed definitions had little impact on patients' priority for treatment. This audit has established a baseline measurement of waiting times for systemic therapy across the United Kingdom. The continuing introduction of novel therapies is likely to have a significant effect on the service and we recommend that service managers model the likely impact on resource requirements. In addition, urgent treatment should be clearly defined as that required within 24 h (maximum 48 h) to avoid the risk of clinical deterioration, particularly in patients with acute leukaemia, lymphoma or germ cell tumour
Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival
Given the survival benefits of adjuvant chemotherapy for advanced ovarian cancer (OC), we examined the associations of survival with the time interval from debulking surgery to initiation of chemotherapy and with the duration of chemotherapy. Among patients ⩾65 years with stages III/IV OC diagnosed between 1991 and 2002 in the Surveillance, Epidemiology, and End Results-Medicare database, we developed regression models of predictors of the time interval from surgery to initiation of chemotherapy and of the total duration of chemotherapy. Survival was examined with Cox proportional hazards models. Among 2558 patients, 1712 (67%) initiated chemotherapy within 6 weeks of debulking surgery, while 846 (33%) began treatment >6 weeks. Older age, black race, being unmarried, and increased comorbidities were associated with delayed initiation of chemotherapy. Delay of chemotherapy was associated with an increase in mortality (hazard ratio (HR)=1.11; 95% CI, 1.0–1.2). Among 1932 patients in the duration of treatment analysis, the 1218 (63%) treated for 3–7 months had better survival than the 714 (37%) treated for ⩽3 months (HR=0.84; 95% CI, 0.75–0.94). This analysis represents one of the few studies describing treatment delivery and outcome in women with advanced OC. Delayed initiation and early discontinuation of chemotherapy were common and associated with increased mortality
Rudimentary G-Quadruplex-Based Telomere Capping In Saccharomyces Cerevisiae
Telomere capping conceals chromosome ends from exonucleases and checkpoints, but the full range of capping mechanisms is not well defined. Telomeres have the potential to form G-quadruplex (G4) DNA, although evidence for telomere G4 DNA function in vivo is limited. In budding yeast, capping requires the Cdc13 protein and is lost at nonpermissive temperatures in cdc13-1 mutants. Here, we use several independent G4 DNA-stabilizing treatments to suppress cdc13-1 capping defects. These include overexpression of three different G4 DNA binding proteins, loss of the G4 DNA unwinding helicase Sgs1, or treatment with small molecule G4 DNA ligands. In vitro, we show that protein-bound G4 DNA at a 3\u27 overhang inhibits 5\u27-\u3e 3\u27 resection of a paired strand by exonuclease I. These findings demonstrate that, at least in the absence of full natural capping, G4 DNA can play a positive role at telomeres in vivo
- …